NLS Pharmaceutics Expands DOXA Platform with AEX-6xx Series.

NLS Pharmaceutics and Aexon Labs expand their DOXA platform with the AEX-6xx series, a new generation of small molecules targeting arousal stability, cognition, and neuroprotection. Lead compound AEX-635 modulates MRP1, potentially enhancing neuroprotective effects and improving CNS drug bioavailability, especially in conditions such as Parkinson's disease and gliopathies. The expansion is supported by a solid cash position and strategic funding outlook.